MGTX

MeiraGTx Holdings PLC

MGTX, USA

MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

https://meiragtx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MGTX
stock
MGTX

MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake Yahoo Finance

Read more →
MGTX
stock
MGTX

Discipline and Rules-Based Execution in MGTX Response news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$27.5

Analyst Picks

Strong Buy

3

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-16.89

Low 1

High 3

Return on Equity (ROE)

-

Very High

124.55 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-26.66 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3,128.05 %

Low 5%

High 15%

Investors

* Institutions hold a combined 79.23% of the total shares of MeiraGTx Holdings PLC

1.

Perceptive Advisors LLC

(15.6948%)

since

2025/06/30

2.

Sanofi

(15.1624%)

since

2025/06/30

3.

Johnson & Johnson

(8.2552%)

since

2025/06/30

4.

Adage Capital Partners Gp LLC

(7.5013%)

since

2025/06/30

5.

Prosight Management, LP

(5.7024%)

since

2025/06/30

6.

Rubric Capital Management LP

(4.6322%)

since

2025/06/30

7.

BlackRock Inc

(3.5581%)

since

2025/06/30

8.

683 Capital Management LLC

(3.3438%)

since

2025/06/30

9.

J. Goldman & Co LP

(2.5415%)

since

2025/06/30

10.

Knoll Capital Management LP

(1.5538%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(1.2756%)

since

2025/08/31

12.

Erste Asset Management GmbH

(0.9816%)

since

2025/06/30

13.

Millennium Management LLC

(0.976%)

since

2025/06/30

14.

State Street Corp

(0.848%)

since

2025/06/30

15.

22NW, LP

(0.7291%)

since

2025/06/30

16.

Geode Capital Management, LLC

(0.6931%)

since

2025/06/30

17.

Long Focus Capital Management, LLC

(0.6523%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(0.5648%)

since

2025/06/30

19.

Vanguard Group Inc

(0.5229%)

since

2025/06/30

20.

Fidelity Small Cap Index

(0.5207%)

since

2025/06/30

21.

iShares Biotechnology ETF

(0.4046%)

since

2025/08/31

22.

Royal Bank of Canada

(0.3777%)

since

2025/06/30

23.

iShares Russell 2000 Growth ETF

(0.3417%)

since

2025/08/31

24.

Northern Trust Corp

(0.3405%)

since

2025/06/30

25.

Royce Smaller-Companies Growth Svc

(0.2697%)

since

2025/06/30

26.

Vanguard Russell 2000 ETF

(0.2472%)

since

2025/07/31

27.

Vanguard Health Care ETF

(0.1664%)

since

2025/07/31

28.

State St Russell Sm Cap® Indx SL Cl I

(0.1478%)

since

2025/08/31

29.

Schwab Small Cap Index

(0.1302%)

since

2025/07/31

30.

NT R2000 Index Fund - NL

(0.1253%)

since

2025/06/30

31.

iShares Micro-Cap ETF

(0.1175%)

since

2025/08/31

32.

iShares Russell 2000 Value ETF

(0.1155%)

since

2025/08/31

33.

Galileo - Biotech Innovation Fund S USD

(0.1095%)

since

2025/02/28

34.

NT R2000 Index Fund - DC - NL - 3

(0.0999%)

since

2025/06/30

35.

Russell Inv Tax-Managed US Mid&Sm Cap S

(0.0987%)

since

2025/07/31

36.

Nuveen Equity Index R6

(0.0948%)

since

2025/07/31

37.

SPDR® Russell 2000 US Small Cap ETF

(0.091%)

since

2025/08/31

38.

iShares Russell 2000 Small-Cap Idx Instl

(0.0885%)

since

2025/07/31

39.

Russell 2500™ Index Fund F

(0.0818%)

since

2025/06/30

40.

Nuveen Small Cap Blend Idx R6

(0.075%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.368

Latest Release

Date

2025-09-30

EPS Actual

-0.62

EPS Estimate

-0.5

EPS Difference

-0.12

Surprise Percent

-24%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.